Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

S. M.Qasim Hussaini; Arjun Gupta; Kelly E. Anderson; Jeromie M. Ballreich; Lauren Hersch Nicholas; G. Caleb Alexander

doi:10.1001/jamanetworkopen.2022.1117

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

S. M.Qasim Hussaini, Arjun Gupta, Kelly E. Anderson, Jeromie M. Ballreich, Lauren Hersch Nicholas, G. Caleb Alexander

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E221117
Journal	JAMA Network Open
DOIs	https://doi.org/10.1001/jamanetworkopen.2022.1117
State	Accepted/In press - 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jamanetworkopen.2022.1117

Cite this

@article{ee487b35dc3446ac950efe8d029b5fef,

title = "Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019",

author = "Hussaini, {S. M.Qasim} and Arjun Gupta and Anderson, {Kelly E.} and Ballreich, {Jeromie M.} and Nicholas, {Lauren Hersch} and Alexander, {G. Caleb}",

year = "2022",

doi = "10.1001/jamanetworkopen.2022.1117",

language = "English (US)",

pages = "E221117",

journal = "JAMA Network Open",

issn = "2574-3805",

publisher = "American Medical Association",

}

TY - JOUR

T1 - Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

AU - Hussaini, S. M.Qasim

AU - Gupta, Arjun

AU - Anderson, Kelly E.

AU - Ballreich, Jeromie M.

AU - Nicholas, Lauren Hersch

AU - Alexander, G. Caleb

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85125844107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125844107&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2022.1117

DO - 10.1001/jamanetworkopen.2022.1117

M3 - Letter

C2 - 35254434

AN - SCOPUS:85125844107

SN - 2574-3805

SP - E221117

JO - JAMA Network Open

JF - JAMA Network Open

ER -

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this